PADAGIS ISRAEL
GenericsPADAGIS ISRAEL is a generic drug manufacturer focused on Dermatology, Immunology, Oncology.
PADAGIS ISRAEL at a Glance
- Strong track record with 100% execution quality across 21 trials
- Fast trial execution (10 months median completion)
PADAGIS ISRAEL's Key Drugs
PADAGIS ISRAEL's core commercial portfolio centers on CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, ADAPALENE AND BENZOYL PEROXIDE, spanning Dermatology and Immunology — its most strategically important drugs approved in the last 15 years.
Plaque Psoriasis
Seasonal Allergic Rhinitis
Acne Vulgaris
Vulvovaginal Candidiasis
PADAGIS ISRAEL's Recent FDA Approvals
New NDA/BLA approvals for PADAGIS ISRAEL over the last two years — novel drugs only, excluding generics and label supplements.
PADAGIS ISRAEL's Therapeutic Areas
PADAGIS ISRAEL's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PADAGIS ISRAEL's Top Competitors
PADAGIS ISRAEL's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PADAGIS ISRAEL Pipeline Snapshot
Active clinical trials for PADAGIS ISRAEL across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 21/21 completed
- • Speed: 10 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (1)
Company Info
- First Approval
- 2000-05-24
- Latest
- 2026-06-03
- Applications
- 81
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges